Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.88 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | TSHR | P16473 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.88 |
| ▸ | EYA2 | O00167 | 1/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | ACE | P12821 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentetic Acid SCHEMBL598927 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL11041213 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 | |
| Edetic Acid SCHEMBL10891778 | 0.97 | TDP1 (0.88) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL6241488 | 0.94 | TDP1 (0.88) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL15950012 | 0.94 | TDP1 (0.88) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL6566728 | 0.94 | TDP1 (0.88) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL10888673 | 0.94 | TDP1 (0.88) | TDP1BLMPMP22KDM4EALOX15 | |
| Edetic Acid SCHEMBL3735469 | 0.94 | TDP1 (0.93) | TDP1BLMPMP22KDM4EALOX15 | |
| Edetic Acid SCHEMBL119008 | 0.94 | TDP1 (0.93) | TDP1BLMPMP22KDM4EALOX15 | |
| Edetic Acid SCHEMBL6249529 | 0.94 | TDP1 (0.93) | TDP1BLMPMP22KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768415-A | Novel therapeutic and/or prophylactic agent for coronavirus infection (COVID-19) | 日本纽翱医药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-111417390-A | Pharmaceutical composition for enhancing antitumor effect of immune checkpoint inhibitor | 思佰益药业股份有限公司 | 2020-07-14 | — | — | CN | disclosed |
| EP-2767276-B1 | IMPROVING / PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE | SBI PHARMACEUTICALS CO LTD (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-9539225-B2 | Anemia of cancer improving/prophylactic agent | SBI PHARMACEUTICALS CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9475755-B2 | Prophylactic agent for chronic kidney disease | SBI Pharmaceuticals Co., Ltd (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20140288173-A1 | ANEMIA OF CANCER IMPROVING/PROPHYLACTIC AGENT | SBI PHARMACEUTICALS CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-20140256806-A1 | PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE | SBI PHARMACEUTICALS CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2767276-A1 | IMPROVING / PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE | SBI Pharmaceuticals Co., Ltd. (JP) | 2014-08-20 | — | — | EP | disclosed |
| EP-2767280-A1 | ANEMIA OF CANCER IMPROVING / PROPHYLACTIC AGENT | SBI Pharmaceuticals Co., Ltd. (JP) | 2014-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288173-A1 | ANEMIA OF CANCER IMPROVING/PROPHYLACTIC AGENT | ALAD, ASNS, AAAS | TDP1 3004/4885BLM 3328/4885PMP22 3164/4885 |
| US-20140256806-A1 | PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE | ALAD, GLS, AAAS | TDP1 3444/4885BLM 4024/4885PMP22 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.